
Oculis Holding AG (NASDAQ:OCS – Free Report) – HC Wainwright cut their FY2026 EPS estimates for shares of Oculis in a research report issued on Tuesday, November 17th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($2.27) for the year, down from their previous estimate of ($1.63). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.65) EPS, Q1 2027 earnings at ($0.66) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.69) EPS.
Other research analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. reduced their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Finally, Guggenheim decreased their price target on Oculis to $40.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.57.
Oculis Stock Down 5.1%
Shares of NASDAQ OCS opened at $7.06 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.41 and a quick ratio of 10.41. The company has a market cap of $409.34 million, a P/E ratio of -4.13 and a beta of 0.67. Oculis has a 1 year low of $6.78 and a 1 year high of $34.47. The firm has a 50-day simple moving average of $8.33 and a two-hundred day simple moving average of $17.34.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.10. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.24%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.26 million.
Institutional Investors Weigh In On Oculis
Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in shares of Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after acquiring an additional 5,813 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Oculis in the third quarter valued at approximately $74,000. Aquatic Capital Management LLC bought a new position in Oculis in the third quarter worth approximately $134,000. Himension Capital Singapore PTE. LTD. bought a new position in Oculis in the first quarter worth approximately $503,000. Finally, Alps Advisors Inc. grew its stake in Oculis by 40.7% in the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after purchasing an additional 23,600 shares in the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Recommended Stories
- Five stocks we like better than Oculis
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
